BioNTech (NASDAQ:BNTX) Trading Down 3.4%

BioNTech SE (NASDAQ:BNTX)’s share price fell 3.4% on Thursday . The stock traded as low as $95.60 and last traded at $95.85. 236,594 shares were traded during trading, a decline of 67% from the average session volume of 706,392 shares. The stock had previously closed at $99.27.

Wall Street Analysts Forecast Growth

Several brokerages have commented on BNTX. Deutsche Bank Aktiengesellschaft upgraded shares of BioNTech from a “hold” rating to a “buy” rating and set a $95.00 price objective for the company in a research note on Wednesday, August 7th. TD Cowen dropped their target price on BioNTech from $98.00 to $85.00 and set a “hold” rating on the stock in a report on Tuesday, August 6th. HC Wainwright reiterated a “buy” rating and issued a $113.00 target price on shares of BioNTech in a research note on Tuesday, August 27th. HSBC upgraded BioNTech from a “hold” rating to a “buy” rating in a research report on Friday, August 2nd. Finally, Hsbc Global Res upgraded shares of BioNTech from a “hold” rating to a “strong-buy” rating in a research report on Friday, August 2nd. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating, five have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $109.09.

BioNTech Trading Up 2.2 %

The company has a quick ratio of 7.40, a current ratio of 7.54 and a debt-to-equity ratio of 0.01. The stock has a market capitalization of $24.12 billion, a price-to-earnings ratio of 198.54 and a beta of 0.23. The company’s 50-day moving average is $85.91 and its 200-day moving average is $89.37.

BioNTech (NASDAQ:BNTX) last released its quarterly earnings data on Monday, August 5th. The company reported ($3.36) EPS for the quarter, missing analysts’ consensus estimates of ($2.02) by ($1.34). The business had revenue of $128.70 million during the quarter, compared to analyst estimates of $134.98 million. BioNTech had a negative net margin of 18.69% and a negative return on equity of 2.54%. The company’s revenue was down 23.3% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.86) earnings per share. Research analysts anticipate that BioNTech SE will post -2.8 earnings per share for the current fiscal year.

Institutional Investors Weigh In On BioNTech

A number of institutional investors and hedge funds have recently made changes to their positions in BNTX. Candriam S.C.A. boosted its position in shares of BioNTech by 261.2% during the 2nd quarter. Candriam S.C.A. now owns 578,998 shares of the company’s stock worth $46,526,000 after purchasing an additional 418,695 shares during the period. Neuberger Berman Group LLC acquired a new stake in shares of BioNTech in the fourth quarter valued at $1,562,000. US Bancorp DE raised its holdings in shares of BioNTech by 420.7% in the 4th quarter. US Bancorp DE now owns 28,614 shares of the company’s stock valued at $3,020,000 after buying an additional 23,119 shares during the period. Goldman Sachs Group Inc. lifted its stake in BioNTech by 17.2% during the 4th quarter. Goldman Sachs Group Inc. now owns 182,878 shares of the company’s stock worth $19,301,000 after acquiring an additional 26,777 shares in the last quarter. Finally, Harding Loevner LP purchased a new position in BioNTech during the 4th quarter valued at about $410,984,000. 15.52% of the stock is owned by hedge funds and other institutional investors.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.